Clinical trials: Localized Prostate Adenocarcinoma, active
Prostate Adenocarcinoma, Stage I Prostate Cancer American Joint Committee on Cancer (AJCC) v8
Focal Radiation Therapy (HDR-Brachytherapy) for the Treatment of Prostate Cancer
This clinical trial tests the effect of focal radiation therapy, high dose rate-brachytherapy (HDR-BT), in treating patients with prostate cancer.
- Conditions
- Prostate Adenocarcinoma, Stage I Prostate Cancer American Joint Committee on Cancer (AJCC) v8, Stage II Prostate Cancer AJCC v8
- Trial name
- NCT07468903
- Testing
- Biopsy Procedure, Biospecimen Collection, High-Dose Rate Brachytherapy
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Jonsson Comprehensive Cancer Center
PSA Level Greater Than 0.03, PSA Progression
Stereotactic Body Radiation Therapy in Treating Patients With Localized Prostate Cancer That Have Undergone Surgery
This phase II trial studies how well stereotactic body radiation therapy works in treating patients with prostate cancer that has not spread to other parts of the body and have undergone surgery.
- Conditions
- PSA Level Greater Than 0.03, PSA Progression, Stage I Prostate Adenocarcinoma AJCC (American Joint Committee on Cancer ) v7, Stage II Prostate Adenocarcinoma AJCC v7
- Trial name
- NCT03541850
- Testing
- Antiandrogen Therapy, Quality-of-Life Assessment, Stereotactic Body Radiation Therapy
- Where
- 2 sites in United States
- Volunteers
- 92 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Prostate CA, Prostate Cancer (Adenocarcinoma)
Neoadjuvant Darolutamide and Relugolix Combination Preceding Radical Prostatectomy for Prostate Cancer
The goal of this clinical trial is to determine the safety and feasibility of a new combination of darolutamide and relugolix as neoadjuvant therapy preceding radical prostatectomy (RP) for high-risk prostate cancer (PCa) in…
- Conditions
- Prostate CA, Prostate Cancer (Adenocarcinoma), Prostate Cancer Surgery
- Trial name
- NCT06631521
- Testing
- Darolutamide, Relugolix, Radical Prostatectomy
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- AdventHealth
Prostate Adenocarcinoma With Focal Neuroendocrine Differentiation, Prostate Cancer
RET-Targeted Molecular Imaging Probes in Prostate Cancer
The goal of this observational diagnostic imaging study is to evaluate the value of RET-targeted PET/CT molecular imaging in diagnosing neuroendocrine prostate cancer (NEPC) and in assessing disease activity, treatment response…
- Trial name
- NCT07886138
- Testing
- RET-targeted PET/CT molecular imaging, PSMA-targeted PET/CT imaging
- Where
- China
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Xiangya Hospital of Central South University
Prostate Cancer, Prostate Adenocarcinoma
Hypofractionated Accelerated Pelvic Nodal Radiotherapy (GCC 2048)
A phase I trial to determine the safety of delivering three sequentially shorter RT schedules (20, 16, and 12 fractions) of HypoFx pelvic nodal RT in combination with a HypoFx, simultaneous integrated boost (SIB) to the prostate…
- Trial name
- NCT04486755
- Testing
- Hypofractionated Radiation Therapy
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- University of Maryland, Baltimore
Prostate Cancer, Radiation Toxicity
Predicting the Risk of Failure in Patients Undergoing Radiation Therapy for Localized Prostate Cancer
RATIONALE: Gathering information about the Gleason score, prostate-specific antigen (PSA) level, and cancer stage from patients who have undergone radiation therapy for prostate cancer may help doctors predict how patients…
- Trial name
- NCT00769223
- Testing
- medical chart review, questionnaire administration, quality-of-life assessment
- Where
- United States
- Volunteers
- 3,561 people
- Sponsor
- University of California, San Francisco
Localized Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8
Image-Guidance and Online Adaptation With Stereotactic Body Radiation Therapy for the Treatment of Localized Prostate Cancer, MANTICORE Trial
This clinical trial studies the side effects of image-guidance and online adaptation with stereotactic body radiation therapy (SBRT) for the treatment of patients with prostate adenocarcinoma that has not spread to other parts of…
- Conditions
- Localized Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8
- Trial name
- NCT07276438
- Testing
- Biospecimen Collection, Computed Tomography, CT-guided Stereotactic Body Radiation Therapy
- Where
- United States
- Volunteers
- 186 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Prostate Adenocarcinoma, Prostate Cancer
Utilization of Flotufolastat 18F PET for Post-Focal Therapy Prostate Cancer Evaluation
This is a phase II single arm, open-label clinical trial determining diagnostic accuracy of Flotufolastat F18 PET in subjects with prostate adenocarcinoma.
- Trial name
- NCT07568756
- Testing
- Flotufolastat F18 PET
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of California, Irvine
Stage I Prostate Adenocarcinoma AJCC v7, Stage II Prostate Adenocarcinoma AJCC v7
Hypofractionated Proton Beam Therapy for Localized Prostate Cancer
This phase II trial studies the side effects and how well hypofractionated proton beam radiation therapy works in treating patients with prostate cancer that has not spread to nearby lymph nodes or to other parts of the body.
- Trial name
- NCT01950351
- Testing
- Laboratory Biomarker Analysis, Proton Beam Radiation Therapy, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 241 people
- Sponsor
- M.D. Anderson Cancer Center
Localized Prostate Adenocarcinoma
Feasibility of MR-Informed Adaptive Marker-less SBRT in Patients With Bilateral Hip Prostheses Undergoing SBRT for Localized Prostate Cancer
Hip replacements and prostate cancer are independently and both together increasing prevalent in the aging population. In the United States, the prevalence of hip prostheses among men was 1.1 million in 20101, with approximately…
- Trial name
- HIP-PRO (NCT07042256)
- Testing
- Low-field MR-informed adaptive marker-less SBRT for definitive treatment of localized prostate cancer in patients with bilateral hip prostheses
- Where
- Switzerland
- Volunteers
- 13 people
- Sponsor
- University of Zurich
Localized Prostate Carcinoma, Prostate Cancer (Adenocarcinoma)
Online Adaptive Stereotactic Body Radiotherapy for Localized Prostate Cancer
The aim of this phase II international multicenter study is to evaluate the safety, feasibility, and efficacy of CT or MRI-adaptive SBRT, delivered in five weekly fractions, in patients with newly diagnosed localized prostate…
- Conditions
- Localized Prostate Carcinoma, Prostate Cancer (Adenocarcinoma), Prostate Hyperplasia, Lower Urinary Track Symptoms
- Trial name
- X-SMILE (NCT06834152)
- Testing
- radiotherapy
- Where
- 3 sites in Germany, Switzerland
- Volunteers
- 75 people
- Sponsor
- University of Zurich
To Evaluate the Rate of Digestive and Urinary Toxicity
Study Evaluating the Efficacy and the Tolerance of Pelvic-prostatic Hypo-fractionated Radiotherapy Followed by Boost in Patients With Prostate Adenocarcinoma Adverse Intermediate Risk or High Localized Risk
The standard treatment of high-risk prostatic adenocarcinoma is based on pelvic-prostatic external radiotherapy combined with concomitant and adjunctive hormone therapy for a total of 3 years.
- Trial name
- SHORT (NCT03417336)
- Testing
- prostatic boost in brachytherapy with high dose rate (HDR)
- Where
- 2 sites in France
- Volunteers
- 90 people
- Sponsor
- Centre Georges Francois Leclerc
Prostate Cancer (Adenocarcinoma), Prostate Brachytherapy
PRO-BOOST-LC: Whole-Gland Boost Strategies Versus SBRT Monotherapy in PSMA-Staged Localized and Locally Advanced Prostate Cancer
PRO-BOOST-LC is a prospective, multicenter, randomized phase II/III clinical trial for men with localized or locally advanced prostate cancer without lymph node or distant metastases, confirmed using prostate-specific membrane…
- Conditions
- Prostate Cancer (Adenocarcinoma), Prostate Brachytherapy, Stereotactic Body Radiation Therapy (SBRT), Dose Escalation: Solid Tumors
- Trial name
- PRO-BOOST-LC (NCT07426055)
- Testing
- Stereotactic Body Radiotherapy (SBRT) Monotherapy, External Beam Radiotherapy (EBRT) Backbone, High-Dose-Rate Brachytherapy Boost
- Where
- Poland
- Volunteers
- 1,000 people
- Sponsor
- Affidea Nu-med Center of Oncological DIagnostics and Therapy
Prostate Cancer (Adenocarcinoma), Localized Prostate Cancer
68Ga-PSMA-11 PET/MRI for Selecting Men With Prostate Cancer for Focal Therapy
Focal therapy is a minimally invasive treatment option for some men with localized prostate cancer. Unlike surgery or radiation, focal therapy treats only the area of the prostate containing clinically significant cancer, with…
- Trial name
- PSMA-FT (NCT07747493)
- Testing
- Gallium Ga 68 Gozetotide (68Ga-PSMA-11), Intervention Description: Integrated positron emission tomography/magnetic resonance imaging (PET/MRI) combines molecular imaging with high-resolution anatomical MRI to evaluate intraprostatic lesions
- Where
- Canada
- Volunteers
- 8 people
- Sponsor
- University Health Network, Toronto
Prostate Cancer (Adenocarcinoma)
Adaptive Stereotactic Radiotherapy for Localized Prostate Cancer
This study evaluates whether adaptive stereotactic body radiotherapy (SBRT) provides dosimetric advantages compared to non-adaptive SBRT in localized prostate cancer.
- Trial name
- SPAR (NCT07344844)
- Testing
- Low-dose CT imaging before each SBRT session
- Where
- Reunion
- Volunteers
- 100 people
- Sponsor
- Clinique Sainte Clotilde
Prostate Cancer (Adenocarcinoma), Adenocarcinoma of the Prostate
RYZ711 Diagnostic Platform Study
This is a Phase 1/2 multicenter, multi-cohort imaging study to evaluate the safety, tolerability, and diagnostic performance of RYZ711 positron emission tomography/computed tomography (PET/CT) in men with histologically confirmed…
- Conditions
- Prostate Cancer (Adenocarcinoma), Adenocarcinoma of the Prostate, Metastatic Castration-resistant Prostate Cancer (mCRPC), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
- Trial name
- NCT07862582
- Testing
- RYZ711, PSMA PET/CT
- Where
- United States
- Volunteers
- 116 people
- Sponsor
- RayzeBio, Inc.
Adenocarcinoma, Prostate Cancer
Multitargeted Recombinant Ad5 PSA/MUC-1/Brachyury-Based Immunotherapy (TriAdeno) Vaccine With IL-15 Superagonist N-803 in Participants With Clinically Localized Prostate Cancer Undergoing Active Surveillance
Background: Prostate cancer is the second most common cause of cancer-related death among men in the United States. Early-stage, low-grade prostate cancer is managed with active monitoring.
- Conditions
- Adenocarcinoma, Prostate Cancer, Neoplasms, Carcinoma
- Trial name
- NCT07574541
- Testing
- TriAdeno vaccine, N-803
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Adenocarcinoma, Stage IIIB Prostate Cancer AJCC v8
Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation
This phase II trial tests how well carboplatin before surgery works in treating patients with high-risk prostate cancer and an inherited BRCA1 or BRCA2 gene mutation.
- Conditions
- Prostate Adenocarcinoma, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8
- Trial name
- NCT05806515
- Testing
- Biospecimen Collection, Carboplatin, Chest Radiography
- Where
- 133 sites in United States
- Volunteers
- 44 people
- Sponsor
- SWOG Cancer Research Network
Prostate Adenocarcinoma, Localized Prostate Carcinoma
Two-fraction HDR Monotherapy for Localized Prostate Cancer
This is a single center single arm prospective pilot study investigating the safety of high dose rate (HDR) brachytherapy as monotherapy delivered in 2 fractions 3 hours apart.
- Trial name
- NCT05665738
- Testing
- High Dose Rate Monotherapy
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of California, San Francisco
Prostate Cancer, Prostate Adenocarcinoma
A Comparison of TULSA Procedure vs. Radical Prostatectomy in Participants With Localized Prostate Cancer
Men with localized, intermediate risk prostate cancer will be randomized to undergo either radical prostatectomy or the TULSA procedure, with a follow-up of 10 years in this multi-centered randomized control trial.
- Trial name
- CAPTAIN (NCT05027477)
- Testing
- Radical Prostatectomy, TULSA Procedure
- Where
- 22 sites in United States, Canada and 1 more
- Volunteers
- 201 people
- Sponsor
- Profound Medical Inc.